Deutsche Bank ADR Virtual Investor Conference: Presentations Accessible for Online Viewing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Source: Globenewswire
Event Announcement: The Depositary Receipts Virtual Investor Conference (dbVIC) was held on November 4, 2025, and the presentations are now available for online viewing for 90 days.
Participating Companies: Notable companies that presented include HUTCHMED, First Pacific Company, Viomi Technology, Epiroc, and Deutsche Lufthansa, among others.
Investor Access: Investors, advisors, and analysts can download materials from the companies' resource sections, enhancing their engagement with the presentations.
About Virtual Investor Conferences: VIC is a leading platform that facilitates direct presentations from publicly traded companies to investors, offering enhanced capabilities for investor engagement and communication.
Analyst Views on RADX
Wall Street analysts forecast RADX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RADX is 20.33 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.880
Low
15.00
Averages
20.33
High
30.00
Current: 4.880
Low
15.00
Averages
20.33
High
30.00
About RADX
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
